POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Resources for patients
and caregivers.
Share these helpful tools and resources with patients with multiple myeloma and their caregivers.
Treatment Overview
A brochure for patients who
have been prescribed
POMALYST® (pomalidomide).
Treatment Calendar
Create a custom treatment calendar
to help patients stay organized with
treatments/appointments.
Caregiver Brochure
A brochure offering caregivers information and resources to help them care for patients with multiple myeloma.
DownloadFull Prescribing Information
Explore the full Prescribing
Information, including Boxed
WARNINGS, for POMALYST.